To assess the possible impact of GR dysfunction at the peripheral gene expression level, we collected blood samples from a cohort of 11 presymptomatic (PreSCA3) and 30 symptomatic patients with SCA3 (SCA3), each with their respective control (CTRL) group (Tables 2 and 3). The gene discussed is NR3C1; the disease is Spinocerebellar ataxia type 3.